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Background: The aim of this study was to investigate the relationship between changes in serum ferritin
concentrations and the development of metabolic syndrome (MetS) and its components over a 6.5 year follow-up
period in Finnish adults.
Methods: Adults born in Pieksämäki, Finland, in 1942, 1947, 1952, 1957, and 1962 (n = 1294) were invited to health
checkups between 1997 and 1998 and 2003 and 2004. All of the required variables for both checkups were
available from 691 (53%) subjects (289 men and 402 women). MetS was defined by the National Cholesterol
Education Program criteria.
Results: During the 6.5-year follow-up period, 122 (18%) subjects developed incident cases of MetS. Increases in
serum ferritin levels were significantly higher in both women and men with incident MetS compared with women
and men without MetS (p = 0.04, p = 0.03). Also, serum ferritin levels increased significantly less in women in
whom the criteria for MetS resolved during the follow-up period (p = 0.01). Increases in serum ferritin levels were
significantly lower in women in whom the glucose criterion for MetS resolved, and higher in women for whom the
waist criterion developed (p = 0.01 and p <0.001, respectively). Serum ferritin levels decreased significantly more in
men in whom the triglyceride criterion for MetS resolved during the follow-up period (p = 0.01). There was a clear
and significant correlation between change in serum ferritin level and change in waist circumference both in
men and women (p <0.001, p <0.01). In addition, correlations between change in serum ferritin level and change
in plasma triglyceride as well as glucose levels were strongly positive in men (p <0.001). There was negative
correlation between change in serum ferritin and plasma high density cholesterol level both in men and women.
Conclusions: Increases in serum ferritin over a 6,5 year period are associated with development of MetS in both
men and women. Whereas, lower increases in serum ferritin over the same timeframe are associated with
resolution of hypertriglyceridemia in men and hyperglycemia in women. Increases in waist circumference was
positively correlated with increases in serum ferritin in both men and women.
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Metabolic syndrome (MetS) is a pathophysiological dis-
order with a clustering of risk factors for cardiovascular
disease and type 2 diabetes [1,2]. Ferritin, an intracellular
protein and key regulator of iron homeostasis, is a cli-
nical measure of body iron stores [3]. Elevated body iron
stores could promote oxidative stress, and in this man-
ner affect the pathogenesis of insulin resistance [4-6].
Several studies have reported an association between ele-
vated serum ferritin levels and elevated serum insulin,
fasting glucose, insulin resistance [7-9], and diabetes
[10-16]. Cross-sectional studies have found an asso-
ciation between metabolic syndrome (MetS) and serum
ferritin levels [17-23]. No studies have been done to in-
vestigate the relationships between changes in serum fer-
ritin levels and development of MetS components in
both men and women. One prospective study previously
evaluated an association between baseline serum ferritin
levels and future MetS [24].
The aim of this population-based study was to investi-
gate the relationship between changes in serum ferritin
over a 6.5 year period and the development and reso-
lution of MetS and its components in Finnish adults.
Methods
All residents of Pieksämäki, a town in Finland, who were
born in 1942, 1947, 1952, 1957, and 1962 (n = 1,294) were
invited to receive a health checkup between 1997 and
1998 (baseline visit) and again between 2003 and 2004. Of
those invited, 923 (71%) participated in the first checkup,
and 693 subjects (54%) attended both checkups. All vari-
ables analyzed in the present study were available from
691 subjects (289 men and 402 women). All the subjects
completed a questionnaire that asked about their medi-
cations, smoking habits, alcohol consumption, and level
of physical activity. The protocol was approved by the
Kuopio University Hospital Ethics Committee. All partici-
pants provided written informed consent.
Clinical and laboratory measurements
Health evaluations were performed by the same 2 nurses
at both checkups. Sitting blood pressure was measured
with a mercury sphygmomanometer after 15 minutes of
rest. The measurement was repeated 5 minutes later,
and the mean of the 2 measurements was used in the
statistical analyses. Waist circumference was measured
from the midpoint between the lateral iliac crest and the
lowest rib to the nearest 0.5 cm. Weight and height were
measured to the nearest 0.1 kg and 0.5 cm, respectively.
Blood samples were taken after an overnight fast.
Plasma was separated by centrifugation and the samples
were frozen immediately and stored at -70C. Samples
were analyzed in Kuopio regional laboratory during the
year 2010.Plasma glucose concentration was measured using an
automated colorimetric method (Peridochrom Glucose
GOD-PAP; Boehringer Mannheim GmbH, Mannheim,
Germany). Serum triglycerides and cholesterol were
measured from fresh serum samples using glycerol-3-
phosphate oxidase phenol + aminophenazone (PAP) and
cholesterol oxidase-PAP (CHOD-PAP) enzymatic colo-
rimetric methods, respectively (Boehringer Mannheim
GmbH). Serum high-density lipoprotein (HDL) choles-
terol was measured using the same method (CHOD-PAP)
after the precipitation of apolipoprotein B-containing lipo-
protein particles by phosphotungstic acid and magnesium.
High-sensitivity C-reactive protein (hs-CRP) was mea-
sured with an Immulite® analyzer and a DPC high-
sensitivity CRP assay (Diagnostics Products Corporation,
Los Angeles, CA, USA). Serum ferritin concentration was
analyzed using an electrochemiluminescence immuno-
assay (Roche Diagnostics GmbH, Mannheim, Germany).
In order to exclude liver storage disease plasma alanine
aminotransferase (P-ALT) was measured using a kinetic
method according to the International Federation of
Clinical Chemistry and Laboratory Medicine using a
cobas® 6000 (c 501) analyzer (Hitachi High Technology
Co, Tokyo, Japan).
At the beginning and end of the study period, MetS
was defined according to the new harmonized criteria
[23]. Subjects with 3 or more of the following compo-
nents were classified as having metabolic syndrome: 1)
waist circumference ≥102 cm for men and ≥88 cm for
women 2) fasting triglycerides ≥1.7 mmol/L or treatment
for dyslipidemia 3) serum HDL cholester <1.03 mmol/L
for men and <1.29 mmol/L for women or treatment for
dyslipidemia 4) systolic blood pressure ≥130 mmHg or
diastolic blood pressure ≥85 mmHg or the use of
antihypertensive medication 5) fasting plasma glucose
of ≥5.6 mmol/L or the use of medication for hyperglycemia.
Statistical analyses
The results are expressed as means and standard devia-
tions (SDs) for continuous variables and as proportions
for categorical variables. The normality of variables was
evaluated by the Shapiro-Wilk W-test. Statistical com-
parisons between the groups were performed using the
chi-square test, t-test, or bootstrap-type t-test as appro-
priate. Bootstrap type analysis of covariance was also
used to compare the groups as measurements. In these
analyses, the baseline variables of age, smoking, physical
activity, serum ferritin levels, body mass index and hs-
CRP were used as covariates. Partial correlations were
calculated between chance in serum ferritin level and
chance in levels of MetS components and adjusted for
age, and baseline smoking, physical activity, alcohol use,
serum ferritin concentration, body mass index, and
hs-CRP. For all analyses, p <0.05 was considered significant.
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All variables from both checkups were available for 691
subjects (289 men and 402 women). The baseline cha-
racteristics of the study participants are presented in
Table 1. At baseline, MetS was present in 31% of the
subjects. During the follow-up time, 122 (18%) incident
cases of MetS developed and 44 (6%) cases of MetS re-
solved (data not shown).
Development of MetS and MetS components in relation
to changes in serum ferritin levels during the follow-up
period are shown in Figure 1. All results were adjusted for
the baseline variables of age, smoking, physical activity,
use of alcohol, serum ferritin level, body mass index and
hs-CRP. Serum ferritin level was significantly higher both
in women and men with incident MetS compared with
women and men without MetS (p = 0.04, p = 0.03). Serum
ferritin levels increased significantly less in women in
whom the criteria for MetS resolved during the follow-up
period compared with women in whom the MetS criteria
remained (p = 0.01). Increases in serum ferritin levels were
significantly lower in women in whom the glucose cri-
terion of MetS resolved during the follow-up period
compared with women in whom the glucose criterionTable 1 Baseline clinical and life-style characteristics of the st
Characteristics Men N = 289 (42%)
MetS criteria present, n (%) 98 (34)
Age, years, mean (SD) 45.3 (6.2)
BMI, mean (SD) 26.8 (3.5)
Waist, cm, mean (SD) 94.2 (10.2)
FP-glucose mmol/L, mean (SD) 5.9 (0.9)
BP systolic, mmHg, mean (SD) 137.7 (16.5)
BP diastolic, mmHg, mean (SD) 83.5 (9.7)
HDL-C, mmol/L, mean (SD) 1.3 (0.3)
Triglycerides, mmol/L, mean (SD) 1.7 (1.3)
ALT (U/L) mean (SD) 18.0 (10.9)
Hs-CRP (mg/L), mean (SD) 1.7 (3.9)
Life-style factors, n (%)
Current smoker 80 (28)
Current use of alcohol
Low (nothing) 36 (12)
Moderate 167 (58)
High 86 (30)




BMI: Body mass index; FP-glucose: fasting plasma glucose; BP systolic: systolic blood p
Hs-CRP: high sensitivity C-reactive protein; ALT: alanine aminotransferase.
Current use of alcohol was considered low with no use of alcohol, moderate with u
was considered to be high in subjects who exercised at least 30 minutes daily in th
week, and low if exercising frequency was less than three times per week.remained (p = 0.01). Serum ferritin levels decreased sig-
nificantly more in mean whom the MetS triglyceride cri-
teria for triglycerides resolved during the follow-up period
compared to men who continued to meet the MetS cri-
teria for triglycerides (p = 0.004). Also, there was a statis-
tical trend suggesting an increase in serum ferritin over
the follow-up period was associated with the development
of hypertriglyceridemia compared to men who did not
develop hypertriglyceridemia (p = 0.05). Increases in
serum ferritin were significantly associated with increases
in waist circumference in women during the follow-up
period (p = 0.0001). Changes in ferritin levels between
subjects whose HDL or blood pressure criterion deve-
loped or resolved during follow-up time did not differ
significantly.
Partial correlations between change in serum ferritin
level and change in levels of MetS components are
shown in Table 2. All results are adjusted for the base-
line variables of age, smoking, physical activity, use of al-
cohol, serum ferritin level, body mass index and hs-CRP.
There was strong positive correlation between change in
serum ferritin level and change in waist circumference
both in men and women (p <0.001, p <0.01). In addition,udy population
Women N = 402 (58%) All N = 691
116 (29) 214 (31)
45.1 (6.5) 45.2 (6.2)
26.3 (5.2) 26.6 (4.6)
83.4 (12.3) 87.9 (12.6)
5.6 (0.6) 5.8 (0.8)
132.2 (18.2) 134.4 (0.7)
79.4 (9.5) 81.1 (9.8)
1.5 (0.3) 1.4 (0.3)
1.2 (0.6) 1.4 (1.0)
12.0 (7.6) 14.5 (9.6)
1.7 (2.3) 1.7 (3.0)
82 (20) 162 (23)
85 (21) 121 (18)
290 (72) 457 (66)
27 (7) 113 (16)
54 (13) 95 (14)
240 (60) 401 (58)
108 (27) 195 (28)
ressure; BP diastolic: diastolic blood pressure; HDL-C: high density cholesterol;
se of <2 portions/day, and high with use of >2 portions/day. Physical activity







































































































































































































Figure 1 Legends: All results are adjusted for age, baseline smoking, baseline physical activity, baseline use of alcohol, baseline serum
ferritin level, baseline body mass index and baseline hs-CRP. Waist criterion =Waist >102 cm (male) or >88 cm (female), Glucose criterion = FP-
glucose ≥5.6 mmol/L, Trigly criterion = Triglycerides >1.7 mmol/l or medication for dyslipidemia, HDL criterion = HDL–cholesterol <1.03 mmol/l (men)
or <1.29 mmol/l (women) or medication for dyslipidemia, BP criterion = Systolic blood pressure ≥130 mmHg or diastolic ≥85 mmHg or antihypertensive
medication.
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change in plasma triglyceride as well as glucose levels
were strongly positive in men (p <0.001). There was
negative correlation between change in serum ferritin
and change in plasma HDL cholesterol level both in
men and women. The correlations between change inTable 2 Partial correlations between change in serum
ferritin level and change in levels of MetS components
Men r (95% CI) Women r (95% CI)
Waist 0.21 (0.11 to 0.35)*** 0.15 (0.05 to 0.24)**
Triglycerides 0.20 (0.11 to 0.31)*** 0.09 (-0.01 to 0.17)
HDL-C -0.12 (-0.25 to -0.01)* -0.13 (-0.22 to -0.02)*
Glucose 0.20 (0.07 to 0.33)*** 0.08 (-0.02 to 0.18)
Systolic BP -0.03 (-0.15 to 0.11) 0.02 (-0.07 to 0.12)
Diastolic BP 0.03 (-0.11 to 0.18) 0.03 (-0.09 to 0.13)
*p <0.05, **p <0.01, ***p <0.001.
Adjusted for age, baseline smoking, baseline physical activity, baseline use of
alcohol, baseline serum ferritin level, baseline body mass index and baseline
high sensitivity C-reactive protein.
HDL: high density cholesterol; Systolic BP: systolic blood pressure; Diastolic BP:
diastolic blood pressure.serum ferritin level and change in systolic or diastolic
blood pressure level were not significant.
Discussion
To the best of our knowledge, this is the first follow-up
study evaluating changes in serum ferritin levels in rela-
tionship with the development and resolution of MetS
and components of the MetS in Finnish men and
women.
The increase in serum ferritin levels during the follow-
up period was significantly higher in men and in women
with incident MetS compared with men and women
without incident MetS. In addition, reductions in ferritin
levels were significantly higher in women in whom the
criteria of MetS resolved during the follow-up period.
Previous longitudinal studies have evaluated changes in
ferritin levels and MetS [17,18,20,21,23,25-27]. Also, a
recent longitudinal study showed that elevated ferritin
levels at baseline are associated with future development
of MetS in Korean men [24]. Our study shows not only
an association between baseline increased ferritin levels
and future MetS, but also between increased or reduced
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spectively, during the follow-up period. We also show an
association in both sexes and extended our evaluation to
all MetS components. No previous longitudinal studies
have been done to evaluate the changes in ferritin levels
and development of all MetS components.
We show that serum ferritin was significantly higher
or trended towards being higher in men with the trigly-
ceride criterion for MetS resolved or developed over
the follow-up period. We also show strong positive
association between change in serum ferritin level and
triglyceride level in men. This agrees with previous
cross-sectional studies that found an increasing preva-
lence of elevated triglycerides with increasing serum fer-
ritin levels [20,26]. Other studies showed that higher
ferritin concentrations were associated with increased
triglyceride concentrations [23,27]. Also, higher ferritin
concentrations were previously found to be associated
with an increase in triglyceride levels in male patients
with iron overload and homozygosity for human he-
mochromatosis gene mutations [28].
We show that serum ferritin levels increased signifi-
cantly less in women in whom the glucose criterion for
MetS resolved during the follow up period and also a
strong positive association between change in serum
ferritin level and glucose level in men. Several longitu-
dinal studies have previously shown an association bet-
ween incident diabetes and higher baseline ferritin
levels [10,12-16,29].
Serum ferritin levels increased significantly more in
women whose waist criterion for MetS developed during
the follow up period. Also, there was a strong positive
correlation between change in serum ferritin level and
change in waist circumference both in men and women.
Waist circumference was the only one of the Mets com-
ponents that was positively associated with change in
ferritin level both in men and women, which may indi-
cate the importance of waist circumference in develop-
ment of Mets. Our results are in line with previous
studies that found an association between serum ferritin
levels and central adiposity [30] or an increasing preva-
lence of the MetS waist criterion with increasing serum
ferritin levels [23,26]. However, parts of the previous
cross-sectional studies found no association between the
MetS waist criterion and ferritin levels [27].
The mechanism underlying serum ferritin levels and
the development of MetS is not established, but iron ac-
cumulation and oxidative stress is the leading hypo-
thesis. Iron is involved in multiple cellular processes and
is important for the activity of various enzymes, but it
can also be toxic and cause organic biomolecular oxi-
dation [31]. Ferritin is a clinical measure of body iron
stores [3]. Elevated body iron stores may promote oxi-
dative stress, that may contribute to cellular damageleading to insulin dysfunction, insulin resistance and ab-
normal pancreatic beta-cell function [2,4-6,32]. Hepatic
iron overload has been shown to contribute to peri-
pheral hyperinsulinemia and insulin resistance, while
muscular iron accumulation contributes to decreased
glucose utilization [33]. Moreover, phlebotomy with a
moderate reduction in body iron stores measured by
serum ferritin levels resulted in improvements in gly-
cemic control in patients with MetS in a controlled cli-
nical trial [34]. Chronic oxidative stress is also associated
with oxidation dysfunction of long chain fatty acids in
mitochondria, which can lead to hypertriglyceridemia
in circulation and excessive triglyceride accumulation in
muscle and liver tissue [35,36]. These mechanisms sup-
port our findings that increasing ferritin levels predict
incident MetS and hyperglycemia and hypertriglyce-
ridemia components of MetS.
The iron-regulatory hormone hepcidin control the die-
tary absorption, storage, and tissue distribution of iron.
When hepcidin concentrations are high, iron is trapped in
enterocytes, macrophages, and hepatocytes [37]. Adipose
tissue expressed hepcidin has shown to be enhanced in
obese patients [38]. It is possible, that when waist circum-
ference and central adiposity increase, also hepcidin ex-
pression increases, and altered iron homeostasis leads to a
change in ferritin levels.
Because ferritin is also an acute phase reactant, all re-
sults in our study were adjusted for hs-CRP levels to es-
timate the impact of inflammation. Results remained
significant after adjustment that can suggest that ferritin
concentrations are reflective of storage iron and not the
acute phase response.
Some limitations of our study should be mentioned.
We were not able to exclude persons with known HFE
gene mutations. However, there was no need to exclude
subjects with high baseline serum ferritin levels, con-
sidering that all baseline ferritin levels were less than
750 μg/l (range, 2–722 μg/l). Also, all baseline plasma
ALT levels were less than 120 U/L (range, 4-120 U/L)
that does not refer liver storage disease. Unfortunately,
information about the female participant’s menopausal
status or possible change in status during the follow up
period was not available. Mean ferritin levels are known
to be higher in premenopausal women than in postme-
nopausal ones [26,39]. Also, information about the nutri-
tional content of subjects’ diets or their consumption of
dietary supplements like iron or antioxidants were not
available. The relatively small number of MetS cases that
resolved during the follow up period is also a limitation,
and could have affected the non-significant results ob-
served in men. However, the longitudinal, population-
based design is the strength of this study.
In conclusion, serum ferritin level works as a follow-
up and risk assessment measure in subjects with
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loping MetS and decreasing levels indicating resolving
hypertriglyceridemia and hyperglycemia.
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